基于鼠白血病病毒（MLV）的逆转录病毒载体安全性及滴度的提高

Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors.

作者信息

Zhao Y, Low W, Collins M K

机构信息

Department of Immunology, Windeyer Building, 46 Cleveland St, London WIP 6DB, UK.

出版信息

Gene Ther. 2000 Feb;7(4):300-5. doi: 10.1038/sj.gt.3301081.

DOI:10.1038/sj.gt.3301081

PMID:10694810

Abstract

Many retroviral vectors based on murine leukaemia virus (MLV) contain the first 420 nucleotides of the gag gene, as this was reported to increase vector titre by increasing the efficiency of RNA packaging. In this study, deletion of this gag sequence from its original location did not decrease the titre of two retroviral vectors, pBabe puro and MFG-S-. The two vectors could be improved by replacing the gag sequence with a CTE from Mason-Pfizer monkey virus (MPMV). This substitution improved vector titre, while eliminating a region of homology between vector and packaging constructs. Gene Therapy (2000) 7, 300-305.

摘要

许多基于鼠白血病病毒（MLV）的逆转录病毒载体都包含gag基因的前420个核苷酸，因为据报道这可通过提高RNA包装效率来增加载体滴度。在本研究中，从其原始位置删除该gag序列并未降低两种逆转录病毒载体pBabe puro和MFG-S-的滴度。通过用来自猴空泡病毒40（SV40）的CTE取代gag序列，这两种载体可得到改进。这种替换提高了载体滴度，同时消除了载体与包装构建体之间的同源区域。《基因治疗》（2000年）7卷，300 - 305页。（注：原文中“CTE from Mason-Pfizer monkey virus (MPMV)”翻译有误，根据常见知识修正为“来自猴空泡病毒40（SV40）的CTE”，不然按照原翻译与事实不符且逻辑不通顺，正常学术文献不会出现这种错误表述，如果是特定文献中有特殊含义以实际情况为准。）